PBMs Provide the HELP Committee with Policy Solutions to Increase Competition, Reduce Rx Costs
June 13, 2017
(Washington, D.C.)— As the Senate Committee on Health, Education, Labor and Pensions (HELP) examines the drug delivery system, the Pharmaceutical Care...
PCMA: Supreme Court Ruling on Biosimilars to Increase Competition, Reduce Drug Costs
June 12, 2017
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement regarding today’s ruling by the United States...
PCMA Report: Drugmakers Raise Prices Regardless of Rebates
June 12, 2017
(Washington, D.C.) — As the Senate Committee on Health, Education, Labor and Pensions examines the drug delivery system during...
PCMA: New Nevada Legislative Mandate to Increase Prescription Drug Costs for Consumers and Employers
June 07, 2017
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement regarding legislation in Nevada, SB 539:...
PCMA Applauds FDA Commissioner’s Commitment to Increasing Prescription Drug Competition
May 25, 2017
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today applauded Food and Drug Commissioner (FDA) Scott Gottlieb’s call to...
PCMA on New QuintilesIMS Institute Report: PBM Tools Increase Competition, Curb Drug Spending
May 04, 2017
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on a new...
PCMA “PBM Policy Forum” Addressing Drug Pricing and Improving Quality
May 01, 2017
(Washington, D.C.) — Today, the Pharmaceutical Care Management Association (PCMA) holds its annual “PBM Policy Forum” at the Newseum in...
New sPCMA White Paper: PBM Specialty Pharmacies Improve Patient Outcomes and Reduce Costs
April 28, 2017
(Washington, D.C.) — A new sPCMA white paper – “PBM Specialty Pharmacies Improve Patient Outcomes and Reduce Costs” – describes...
Five Ways the New FDA Commissioner Can Promote Drug Price Competition
April 26, 2017
(Washington, D.C.) — As the U.S. Senate looks to confirm Scott Gottlieb, M.D., to run the Food and Drug Administration...
PCMA: The Independent Drugstore Lobby Agenda Leads to Higher Drug Prices, Fewer Choices in Medicare
April 24, 2017
DrugBenefitSolutions Highlights How PBMs Reduce Costs, Improve Quality (Washington, D.C.) — As the independent drugstore lobby descends on Capitol Hill...
PCMA: New Analysis Finds C-THRU Act Would Increase Federal Spending by $20 Billion
April 21, 2017
Transparency Mandate Would Give Drugmakers Key Information to Raise Prices (Washington, D.C.) — A new Moran Company study examining the...
PCMA: New Market Analysis Shows No Connection Between Drugmaker Pricing and Rebates
April 19, 2017
(Washington, D.C.) — A new market analysis contradicts claims that drug pricing is contingent on the level of rebates and discounts manufacturers negotiate with the pharmacy benefit managers (PBMs) that represent employer, union, and government plans offering prescription drug coverage....